Knowing the Side Effects of Dengue Vaccination: Muscle Pain and Drowsiness
Dengue fever it is still one of the diseases that should be observed in Indonesia. It is also considered that the treatment for dengue fever can help to eliminate this disease caused by mosquitoes. What are the side effects of the dengue vaccine?
Currently, it is said that the distribution of dengue fever vaccine that can be given to people aged 6-45 in Indonesia has already been approved. BPOM Food and Drug Administration chief Penny K. Lukito said the distribution of dengue fever medicine in Indonesia has been approved.
“From BPOM, he has already received permission to distribute,” he said, Friday (26/8).
However, the Ministry of Health must approve the use of this medicine. BPOM allows distribution only for vaccines associated with diseases such as DHF.
“For the dengue vaccine, it has been approved, it’s just a matter of buying it,” he said.
This dengue drug called Qdenga is produced by IDT Biologika GmbH Germany and released and registered under the name Takeda GmbH Germany.
The results of phase 3 research tests involving more than 20 thousand healthy children and adolescents aged 4-16 years who live in dengue-affected areas have also been conducted. As a result, it has been proven that the vaccine provides protection against dengue fever for up to three years after the vaccine is administered.
With this result, the distribution of this vaccine is allowed in Indonesia. In addition, this medicine can be given later in the age of 6-45.
The use of Qdenga dengue vaccine and its side effects
Qdengue vaccine is included in the Live Attenuated Tetravalent Dengue Vaccine (TDV) which contains 4 types of dengue virus, namely weakened dengue serotype 2 (TDV-2), recombinant dengue serotype 2/1 (TDV-1), and recombinant dengue serotype strains. 2/3 (TDV-3), and recombinant dengue serotype 2/4 (TDV-4).
The TDV-2 vaccine is made from an attenuated form of Dengue virus. Currently, vaccines against serotypes 1, 3, and 4 have been used by replacing the pre-membrane (prM) and envelope (E) genes of TDV-2 with the prM and E genes for the dengue virus. 1, dengue type. 3, and Dengue, type 4.
It is said that this vaccine can prevent a person from contracting dengue fever by 80.2 percent. The effectiveness of preventing someone from being hospitalized for dengue is 95.4 percent.
The side effects that patients experience when infected with this virus are generally mild. Quoted from BPOM, there are many side effects of dengue vaccine. – Pain at the injection site
– Erythema (red spots)
– Swelling is temporary and disappears within 1 to 3 days after administration of the drug.
– Myalgia (muscle pain)
– Asthenia (fatigue)
– Drowsiness (sleepiness)
– Loss of appetite